Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial

Garadacimab 200 mg and 600 mg every 4 weeks significantly reduced the number of monthly
attacks versus placebo and was well tolerated during the study. Garadacimab is an
efficacious, subcutaneous prophylaxis in patients with HAE-C1-INH and warrants phase
3 evaluation.